Conexeu Sciences Inc.
Conexeu Sciences Inc. (CNXU) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. CONEXEU SCIENCES INC. LETTER TO SHARE PURCHASE WARRANTHOLDERS October [●], 2026 TO: The registered Holders of Share Purchase Warrants exercisable at US$2.30 per share Conexeu Sciences Inc. (the "Company") HEREBY GIVES NOTICE that a warrant exercise inducement program (the "Induce
Conexeu Sciences Inc. (CNXU) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities From September 14, 2026 through October 15, 2026, Conexeu Sciences Inc. (the "Company") has issued an aggregate of (i) 1,290,000 unregistered shares of common stock, (ii) 1,333,333 units (each, a "Unit"), with each Unit consisting
Purcell Lynn Sebastian purchased 166,666 indirectly-held shares of Conexeu Sciences Inc. (CNXU) at $3.00 ($0.50M total) on 2026-10-15.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CNXU (Conexeu Sciences Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent CNXU coverage spans corporate actions, earnings and insider activity.
In the last 30 days, CNXU insiders filed 1 SEC Form 4 transaction — 1 purchase ($500K) and no sales. The most active reporter was Purcell Lynn Sebastian with 1 filing.
Potential dilution and share‑cap constraints may pressure the stock price until shareholder approval is obtained.
Dilutive capital raise may exert modest downward pressure on the stock.
Insider purchase suggests confidence, may support price.
The financing likely supports near-term runway for preclinical work, but the warrant and escrow overhang can pressure shares until approvals and dilution clarity.
The news provides a fresh regulatory timeline for a micro‑cap biotech, which may lift sentiment ahead of the filing.
AlphAI scores every news story that mentions CNXU with an AI model for sentiment and relevance, and aggregates insider trades from Conexeu Sciences Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Conexeu Sciences Inc. (CNXU) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. CONEXEU SCIENCES INC. LETTER TO SHARE PURCHASE WARRANTHOLDERS October [●], 2026 TO: The registered Holders of Share Purchase Warrants exercisable at US$2.30 per share Conexeu Sciences Inc. (the "Company") HEREBY GIVES NOTICE that a warrant exercise inducement program (the "Induce
2 min readConexeu Sciences Inc. (CNXU) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities From September 14, 2026 through October 15, 2026, Conexeu Sciences Inc. (the "Company") has issued an aggregate of (i) 1,290,000 unregistered shares of common stock, (ii) 1,333,333 units (each, a "Unit"), with each Unit consisting
2 min readPurcell Lynn Sebastian purchased 166,666 indirectly-held shares of Conexeu Sciences Inc. (CNXU) at $3.00 ($0.50M total) on 2026-10-15.
1 min readConexeu Sciences Inc. (CNXU) raised $5M in a private placement, issuing 1.67M units at $3.00 each, including a warrant. Insiders contributed $250K, pending approval. The funds support preclinical work ahead of a planned 510(k) submission in Q1 2027.
3 min readConexeu Sciences (CNXU) is progressing with manufacturing and regulatory testing for its Ten Minute Tissue wound care device, aiming for an FDA 510(k) submission in Q1 2027. The company reported successful scaled-up batches and preclinical studies. CNXU shares rose 4.17% in premarket trading.
2 min readConexeu Sciences Inc. issued 6,500 shares for consulting services, according to a SEC filing. The company, incorporated in Nevada in 2022, did not disclose revenue or asset values. The offering is exempt under Rule 506(b).
1 min readConexeu Sciences Inc. reported Q3 2026 results with $0 revenue and a net loss of $7.73M, or $(0.29) per share, widening from a $(1.30M) loss year-over-year. The company, listed on Nasdaq since May 2026, is scaling operations and advancing a biomaterial device for a planned FDA submission in Q1 2027.
1 min readConexeu Sciences Inc. reported a wider net loss year-over-year due to higher operating costs after its Nasdaq listing. The company stated cash resources are insufficient for the next twelve months without new financing, attributing the increased expenses to marketing, business development, and personnel investments.
1 min readConexeu Sciences Inc. (CNXU) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02 Unregistered Sales of Equity Securities From June 18, 2026 through September 4, 2026, Conexeu Sciences Inc. (the "Company") has issued an aggregate of 1,448,368 unregistered shares of common stock and 202,500 unregistered common stock purchase warrants pursuant to vario
1 min readJourney Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.
3 min read
